Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Discovery & Development Drug Delivery, Formulation, Bioprocessing - Upstream & Downstream, Bioprocessing - Upstream & Downstream, Ingredients

ADCs Assemble

Antibody drug conjugates (ADCs) have garnered much attention in the industry because of their combination of high selectivity and high potency. However, few have been approved and they remain incredibly challenging to develop and manufacture, not least because of the significant challenges involved in combining the right cytotoxic payload at the optimal sites on the antibody in the most efficient way. These challenges are becoming more acute because of the increasing number of best-in-class ADCs that incorporate inherently hydrophobic DNA-interfering payloads, such as pyrrolobenzodiazepines or duocarmycin payloads. DNA-interfering agents are of high interest to ADC developers because they do not rely on a specific part of the cell cycle, unlike other payloads used in ADCs, such as tubulin inhibitors (for example, auristatins and maytansines). Though the payload only constitutes two percent of the overall ADC composition, it can dramatically increase the propensity of the ADC to aggregate.

Enjoy our FREE content!

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login if you already created an account

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login as a Guest or via Social Media

About the Author

Charlie Johnson

Charlie Johnson is CEO of ADC Bio.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register